Enhanced CB2 immunoreactivity has been observed in the colonic epithelium and some cells of the inflammatory cell infiltrate in CD and UC specimens, suggesting that CB2 might be a relevant target for IBD treatment [34–36]. Here, CNR2 is linked to inflammatory bowel disease.